9 results on '"Jiacheng Hu"'
Search Results
2. Tuning Structure and Properties of Pt Catalysts Confined in Single‐Walled Carbon Nanotubes (SWNTs) for Electrocatalysis
- Author
-
Jiacheng Hu, Linsen Zhou, Ge Sang, and Cigang Xu
- Subjects
Biomaterials ,Renewable Energy, Sustainability and the Environment ,Materials Chemistry ,Energy Engineering and Power Technology - Published
- 2022
3. Intron Retention of DDX39A Driven by SNRPD2 is a Crucial Splicing Axis for Oncogenic MYC/Spliceosome Program in Hepatocellular Carcinoma
- Author
-
Cunjie Chang, Lina Li, Ling Su, Fan Yang, Quanxiu Zha, Mengqing Sun, Lin Tao, Menglan Wang, Kangli Song, Liangyu Jiang, Haojin Gao, Yexin Liang, Chao Xu, Caiyu Yong, Minmin Wang, Jiacheng Huang, Jing Liu, Weiwei Jin, Wenyuan Lv, Heng Dong, Qian Li, Fangtian Bu, Shuanghong Yan, Haoxiang Qi, Shujuan Zhao, Yingshuang Zhu, Yu Wang, Junping Shi, Yiting Qiao, Jian Xu, Benoit Chabot, and Jianxiang Chen
- Subjects
digitoxin ,MYC signaling ,RNA splicing ,Sm proteins ,Science - Abstract
Abstract RNA splicing is a dynamic molecular process in response to environmental stimuli and is strictly regulated by the spliceosome. Sm proteins, constituents of the spliceosome, are key components that mediate splicing reactions; however, their potential role in hepatocellular carcinoma (HCC) is poorly understood. In the study, SNRPD2 (PD2) is found to be the most highly upregulated Sm protein in HCC and to act as an oncogene. PD2 modulates DDX39A intron retention together with HNRNPL to sustain the DDX39A short variant (39A_S) expression. Mechanistically, 39A_S can mediate MYC mRNA nuclear export to maintain high MYC protein expression, while MYC in turn potentiates PD2 transcription. Importantly, digitoxin can directly interact with PD2 and has a notable cancer‐suppressive effect on HCC. The study reveals a novel mechanism by which DDX39A senses oncogenic MYC signaling and undergoes splicing via PD2 to form a positive feedback loop in HCC, which can be targeted by digitoxin.
- Published
- 2024
- Full Text
- View/download PDF
4. Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function
- Author
-
Chang Liu, Fengli Li, Liyuan Chen, Jiacheng Huang, Hongfei Sang, Thanh N. Nguyen, Jeffrey L. Saver, Mohamad Abdalkader, Weiling Kong, Jie Yang, Changwei Guo, Chen Gong, Liping Huang, Yanzhu Pan, Xinxin Wang, Yangmei Chen, Zhongming Qiu, and Wenjie Zi
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Objective Renal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban. Hence, this study aimed to investigate the roles of renal function in determining efficacy and safety of intravenous tirofiban before endovascular treatment (EVT) for acute ischemic stroke patients with large vessel occlusion (LVO). Methods This study was a post hoc exploratory analysis of the RESCUE‐BT trial. The primary outcome was the proportion of patients achieving functional independence (modified Rankin scale 0–2) at 90 days, and the primary safety outcome was the rate of symptomatic intracranial hemorrhage (sICH). Results Among 908 individuals with available serum creatinine, decreased estimated glomerular filtration rate (eGFR) status was noted more commonly in patients with cardioembolic stroke (CE), while large artery atherosclerosis (LAA) was predominant in patients with normal renal function. In LAA with normal renal function, tirofiban was associated with higher rates of functional independence at 90 days (41.67% vs 59.80%, p = 0.003). However, for LVO patients with renal dysfunction, tirofiban did not improve functional outcomes for any of the etiologies (LAA, p = 0.876; CE, p = 0.662; others, p = 0.894) and significantly increased the risk of sICH among non‐LAA patients (p = 0.020). Mediation analysis showed tirofiban reduced thrombectomy passes (12.27%) and drug/placebo to recanalization time (14.25%) mediated its effects on functional independence. Conclusion This present study demonstrated the importance of evaluating renal function before administering intravenous tirofiban among patients with LVO who are planned to undergo EVT.
- Published
- 2024
- Full Text
- View/download PDF
5. Intravenous tirofiban following successful reperfusion in intracranial large artery atherosclerotic stroke: A secondary analysis of a randomized clinical trial
- Author
-
Jiacheng Huang, Weilin Kong, Chang Liu, Jiaxing Song, Jie Yang, Chengsong Yue, Linyu Li, Jinrong Hu, Yan Tian, Zhouzhou Peng, Changwei Guo, Dahong Yang, Xiang Liu, Jian Miao, Xiao Zhang, Fengli Li, Jeffrey L. Saver, and Wenjie Zi
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Objective This study aimed to investigate whether treatment with adjunct intravenous tirofiban is associated with improved outcomes following successful reperfusion in patients with intracranial atherosclerotic stroke. Methods Patients with intracranial large artery atherosclerotic (LAA) stroke and an expanded Treatment in Cerebral Ischemia angiographic score of 2b50 to 3 from the Effect of Intravenous Tirofiban versus Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke (RESCUE BT) trial were included. The primary outcome was the difference in proportion of independent functional outcome (modified Rankin score of 0–2 at 90 days). Safety outcomes included the rates of symptomatic intracranial hemorrhage (sICH) and 90‐day mortality. Results Among the 382 patients with intracranial LAA stroke and successful reperfusion, 175 patients (45.8%) were treated with intravenous tirofiban and 207 (54.2%) with placebo. The proportion of patients with independent functional outcome at 90 days was 54.3% (95 out of 175) with tirofiban and 44.0% (91 out of 207) with placebo (adjusted odds ratio [aOR], 1.58; 95% CI, 1.02–2.44; p = 0.04). Intravenous tirofiban was not significantly associated with an increased risk of sICH (12/175 [6.9%] vs. 11/207 [5.3%]; aOR, 1.41; 95% CI, 0.59–3.34; p = 0.44) or 90‐day mortality (21/175 [12.0%] vs. 34/207 [16.4%]; aOR, 0.71; 95% CI, 0.38–1.31; p = 0.27). Interpretation Among patients with acute intracranial LAA stroke and successful reperfusion following endovascular thrombectomy, adjunct intravenous tirofiban was associated with a higher rate of independent functional outcome, without higher rates of sICH or mortality. Confirmatory randomized trials in these patients are desirable.
- Published
- 2023
- Full Text
- View/download PDF
6. Flow Field‐Induced One‐Step Electrodeposition Process to Fabricate Superhydrophobic Films for Flexible Electronics
- Author
-
Zhixin Kang, Yeming Xian, and Jiacheng Hu
- Subjects
Materials science ,Mechanics of Materials ,Mechanical Engineering ,Process (computing) ,One-Step ,Nanotechnology ,Flow field ,Flexible electronics - Published
- 2021
7. MARVEL: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design
- Author
-
Qingwu Yang, Changwei Guo, Chengsong Yue, Jie Yang, Linyu Li, Zhouzhou Peng, Jinrong Hu, Jiandi Huang, Jiaxing Song, Jiacheng Huang, Weilin Kong, Nizhen Yu, Dahong Yang, Xiang Liu, Duolao Wang, Raul G. Nogueira, Fengli Li, Thanh N. Nguyen, and Wenjie Zi
- Subjects
adjunctive therapy ,corticosteroids ,endovascular therapy ,methylprednisolone ,randomized trial ,trial protocol ,Neurology. Diseases of the nervous system ,RC346-429 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Steroids have pleiotropic neuroprotective actions including the regulation of inflammation and apoptosis which may influence the effects of ischemia on neurons, glial cells, and blood vessels. The effect of low‐dose methylprednisolone in patients with acute ischemic stroke in the endovascular therapy era remains unknown. This trial investigates the efficacy and safety of low‐dose methylprednisolone (2 mg/kg IV for 3 days) as adjunctive therapy for patients with acute ischemic stroke undergoing endovascular therapy within 24 hours from symptom onset. Methods The MARVEL (Methylprednisolone as Adjunctive Therapy for Acute Large Vessel Occlusion: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy) trial is an investigator‐initiated, prospective, randomized, double‐blind, placebo‐controlled multicenter clinical trial. Up to 1672 eligible patients with anterior circulation large‐vessel occlusion stroke presenting within 24 hours from symptom onset are planned to be consecutively randomized to receive methylprednisolone or placebo in a 1:1 ratio across 82 stroke centers in China. Results The primary outcome is the ordinal shift in the modified Rankin scale score at 90 days. Secondary outcomes include 90‐day functional independence (modified Rankin scale score, 0–2). The primary safety end points include mortality rate at 90 days and symptomatic intracerebral hemorrhage within 48 hours of endovascular therapy. Conclusion The MARVEL trial will provide evidence of the efficacy and safety of low‐dose methylprednisolone as adjunctive therapy for patients with anterior circulation large‐vessel occlusion stroke undergoing endovascular therapy.
- Published
- 2024
- Full Text
- View/download PDF
8. Cold‐inducible RNA‐binding protein contributes to intracerebral hemorrhage‐induced brain injury via TLR4 signaling
- Author
-
Kai Zhou, Shengtao Cui, Wei Duan, Jianrong Zhang, Jiacheng Huang, Li Wang, Zili Gong, and Yu Zhou
- Subjects
cold‐induced RNA‐binding protein ,inflammation ,intracerebral hemorrhage ,Toll‐like receptor 4 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Introduction Excessive neuroinflammation aggravates the brain injury caused by intracerebral hemorrhage (ICH), while the upstream mechanisms that initiate neuroinflammation remain unclear. Toll‐like receptor 4 (TLR4) signaling is important to trigger inflammatory responses in ICH, and cold‐inducible RNA‐binding protein (CIRP) has been shown as a novel ligand of TLR4 by recent studies. However, whether the CIRP could trigger the neuroinflammation via activating TLR4 signaling in ICH still needs to be investigated. Methods Human serum CIRP levels were measured using the ELISA kits. Western blot, FJB staining, brain water content, and neurological deficit scores were used to investigate the roles of CIRP in brain injury caused by ICH. Result First, we found increased CIRP levels in the blood of patients with ICH when compared to the control individuals, and the ICH patients with mRS > 2 have higher serum CIRP levels in contrast to those with mRS ≤ 2. In the ICH mice, we also found that brain CIRP protein and mRNA levels were also increased after ICH. Furthermore, using the CIRP−/− mice, we found that CIRP−/− mice had less brain damages showing in less FJB+ cells, reduced brain water content (BWC) and lower neurological deficit scores (NDS) compared to that in WT mice after ICH. Cytokines including IL‐6, TNF‐α, and IL‐1β from CIRP−/− mice were attenuated after ICH. CIRP−/− mice also exhibited reduced TLR4 expression which was accompanied by the decreased activity of NF‐κB. This suggests that TLR4 signaling might be involved in CIRP‐mediated inflammatory injury possibly via NF‐κB activation after ICH. Conclusion Our findings suggest that CIRP may activate TLR4 signaling, and further inducing NF‐κB activation to increase the expression levels of cytokines and aggravate inflammatory injury in ICH. Targeting CIRP may be a promising strategy for ICH treatment.
- Published
- 2020
- Full Text
- View/download PDF
9. Contrast‐enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two‐center study
- Author
-
Xiuming Zhang, Shijian Ruan, Wenbo Xiao, Jiayuan Shao, Wuwei Tian, Weihai Liu, Zhao Zhang, Dalong Wan, Jiacheng Huang, Qiang Huang, Yunjun Yang, Hanjin Yang, Yong Ding, Wenjie Liang, Xueli Bai, and Tingbo Liang
- Subjects
contrast‐enhanced CT ,hepatocellular carcinoma ,microvascular invasion ,multivariable logistic regression ,radiomics ,Medicine (General) ,R5-920 - Abstract
Abstract Background The present study constructed and validated the use of contrast‐enhanced computed tomography (CT)‐based radiomics to preoperatively predict microvascular invasion (MVI) status (positive vs negative) and risk (low vs high) in patients with hepatocellular carcinoma (HCC). Methods We enrolled 637 patients from two independent institutions. Patients from Institution I were randomly divided into a training cohort of 451 patients and a test cohort of 111 patients. Patients from Institution II served as an independent validation set. The LASSO algorithm was used for the selection of 798 radiomics features. Two classifiers for predicting MVI status and MVI risk were developed using multivariable logistic regression. We also performed a survival analysis to investigate the potentially prognostic value of the proposed MVI classifiers. Results The developed radiomics signature predicted MVI status with an area under the receiver operating characteristic curve (AUC) of .780, .776, and .743 in the training, test, and independent validation cohorts, respectively. The final MVI status classifier that integrated two clinical factors (age and α‐fetoprotein level) achieved AUC of .806, .803, and .796 in the training, test, and independent validation cohorts, respectively. For MVI risk stratification, the AUCs of the radiomics signature were .746, .664, and .700 in the training, test, and independent validation cohorts, respectively, and the AUCs of the final MVI risk classifier‐integrated clinical stage were .783, .778, and .740, respectively. Survival analysis showed that our MVI status classifier significantly stratified patients for short overall survival or early tumor recurrence. Conclusions Our CT radiomics‐based models were able to predict MVI status and MVI risk of HCC and might serve as a reliable preoperative evaluation tool.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.